Akari Therapeutics Capital Expenditures (CapEx) Growth & History (AKTX)
Akari Therapeutics's capital expenditures (capex) was $0 for fiscal 2019.
View full Akari Therapeutics company overviewAkari Therapeutics annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2019 | 2019-12-31 | $0 | $0 | — |
| 2018 | 2018-12-31 | $0 | −$36,885 | — |
| 2017 | 2017-12-31 | $36,885 | −$17,865 | −32.63% |
| 2016 | 2016-12-31 | $54,750 | $44,190 | +418.47% |
| 2015 | 2015-12-31 | $10,560 | $10,560 | — |
| 2014 | 2014-12-31 | $0 | $0 | — |
| 2013 | 2013-12-31 | $0 | $0 | — |
| 2012 | 2012-12-31 | $0 | $0 | — |
| 2011 | 2011-12-31 | $0 | $0 | — |
| 2010 | 2010-12-31 | $0 | — | — |
Akari Therapeutics quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2016 | 2016-06-30 | $5,897 | $5,897 | — |
| Q1 2016 | 2016-03-31 | $42,083 | $42,083 | — |
| Q2 2015 | 2015-06-30 | $0 | — | — |
| Q1 2015 | 2015-03-31 | $0 | — | — |
Akari Therapeutics capital expenditures (capex) trends
Over the last five fiscal years, Akari Therapeutics's capital expenditures (capex) increased from $0 to $0, a change of $0. The latest reported quarter, Q2 2016, shows $5,897.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Akari Therapeutics source filings ↗